Tuberous Sclerosis Complex (TSC) affects more than 2000 individuals in Australia and thousands more carers, families and friends who live with the impact of the disease.
TSC tumours can grow in any organ of the body, commonly affecting the brain, skin, heart, lungs and kidneys. TSC can cause epilepsy, developmental delay and autism. There is no known cure for TSC, but with appropriate support most people with TSC can live fulfilling lives.
Tuberous Sclerosis Australia (TSA) empowers people affected by TSC through access to the best treatment options, up to date information and support.
Support TSA. We want to improve the lives of Australians living with TSC but can only do so with your support. Please consider making a tax deductible donation today.
Donate NowLatest News
Clinical trial of topical rapamycin (sirolimus) for facial angiofibromas – some interstate travel funding available
Dr Kate Riney and the team at Queensland Children’s Hospital are currently recruiting patients for a formal phase II/III trial of topical rapamycin (sirolimus) for facial angiofibromas. Some funding for interstate travel is available, making this trial available for... Read More
mTOR inhibitor treatment in TSC children under 2 years of age
The aim of this study was to assess the efficacy and safety of treatment of an mTOR inhibitor in children under 2 years of age. Seventeen children who received early treatment with an mTOR inhibitor were included. The children... Read More
Using the TAND checklist
While most paediatricians and child neurologists have become good at identifying and treating the physical manifestations of TSC, it remains difficult to identify and treat the neuropsychiatric issues commonly associated with TSC. Why the TAND checklist was developed In 2012,... Read More
Everolimus and uncontrolled epilepsy associated with TSC: current perspectives
Up to 90% of patients with TSC have epilepsy and in over half of those, seizure control cannot be achieved by regular antiepileptic drugs. This is commonly known as uncontrolled, refractory, intractable, or drug-resistant epilepsy. Everolimus and sirolimus are both mTOR-inhibiting... Read More
